Rifapentine

Drugs

Volumn 56, Issue 4, 1998, Pages 607-616

  Jarvis, B ^a   Lamb, H M ^a   Tam, C M ^a   Chaulet, P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ETHAMBUTOL; ISONIAZID; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHINA; CLINICAL TRIAL; CROSS RESISTANCE; HUMAN; HYPERURICEMIA; LIVER TOXICITY; LUNG TUBERCULOSIS; META ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; RECURRENCE RISK; SPUTUM CULTURE;

MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 0031736426     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856040-00008     Document Type: Article

References (46)

1. 1. LB Heifets PJ Lindholm-Levy MA Flory 1990 Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis 141 626 30 2155555 10.1164/ajrccm/141.3.626 1:CAS:528:DyaK3cXitFektbw%3D Heifets LB, Lindholm-Levy PJ, Flory MA. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis 1990 Mar; 141: 626–30
2. 2. L Fattorini V Vincent B Li 1996 Type frequency and antimicrobial susceptibility of Mycobacterium avium-intracellulare complex strains isolated in Italy from AIDS and non-AIDS patients J Chemother 8 1 37 42 8835106 1:CAS:528:DyaK28XhvVeqs7k%3D Fattorini L, Vincent V, Li B, et al. Type frequency and antimicrobial susceptibility of Mycobacterium avium-intracellulare complex strains isolated in Italy from AIDS and non-AIDS patients. J Chemother 1996; 8(1): 37–42
3. 3. JM Dickinson DA Mitchison 1987 In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 68 177 82 2834842 10.1016/0041-3879(87)90053-5 1:STN:280:DyaL1c3gsFOisw%3D%3D Dickinson JM, Mitchison DA. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 1987 Sep; 68: 177–82
4. 4. HC Neu 1983 Antibacterial activity of DL473, a C3-substituted rifa-mycin derivative Antimicrob Agents Chemother 24 457 60 6639006 10.1128/AAC.24.3.457 1:CAS:528:DyaL3sXltlKkurc%3D Neu HC. Antibacterial activity of DL473, a C3-substituted rifa-mycin derivative. Antimicrob Agents Chemother 1983 Sep; 24: 457–60
5. 5. V Arioli M Berti G Carniti 1981 Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative J Antibiot Tokyo 34 1026 32 7319918 10.7164/antibiotics.34.1026 1:CAS:528:DyaL3MXlsVCjur8%3D Arioli V, Berti M, Carniti G, et al. Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative. J Antibiot Tokyo 1981 Aug; 34: 1026–32
6. 6. JA García-Rodríguez MJ Muñoz Bellido MJ Fresnadillo 1993 In vitro activities of new macrolides and rifapentine against Bruceila spp Antimicrob Agents Chemother 37 911 3 8494391 10.1128/AAC.37.4.911 García-Rodríguez JA, Muñoz Bellido MJ, Fresnadillo MJ, et al. In vitro activities of new macrolides and rifapentine against Bruceila spp. Antimicrob Agents Chemother 1993 Apr; 37: 911–3
7. 7. Schülin T, Wennersten CB, Ferraro RC, et al. Susceptibility of Legionella spp. to ketolide HMR 3647 and other newer antimicrobials [abstract no. F-250]. Abstr Intersci Conf Antimicrob Agents Chemother 1997 Sep–Oct 1 28: 188
8. 8. Felmingham D, Robbins MJ, Clark S. The in vitro activity of rifampicin and rifapentine against recent clinical bacterial isolates [abstract no. F-35]. Abstr Intersci Conf Antimicrob Agents Chemother 1997 28 Sep–1 Oct: 152
9. 9. Morosini MI, Negri MC, Loza E, et al. Anti-pneumococcal activity of rifapentine [abstract no. E-52]. Abstr Intersci Conf Antimicrob Agents Chemother 1997 28 Sep–1 Oct: 122
10. 10. FG Araujo AA Khan JS Remington 1996 Rifapentine is active in. vitro and in. vivo against Toxoplasma gondii. Antimicrob Agents Chemother 40 1335 7 8725996 1:CAS:528:DyaK28XjtlWmtrY%3D Araujo FG, Khan AA, Remington JS. Rifapentine is active in. vitro and in. vivo against Toxoplasma gondii. Antimicrob Agents Chemother 1996 Jun; 40: 1335–7
11. 11. BM Farr 1995 Rifamycins GL Mandell JE Bennett R Dolin Mandell, Douglas and Bennett’s Principles and practice of infectious diseases 4th Churchill Livingstone New York 317 29 Farr BM. Rifamycins. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995: 317–29
12. 12. P Venkataraman CN Paramasivan R Prabhakar 1993 In. vitro activity of rifampicin, rifapentine and rifabutin against south Indian isolates of Mycobacterium tuberculosis. Indian J Tuberc 40 1 17 20 Venkataraman P, Paramasivan CN, Prabhakar R. In. vitro activity of rifampicin, rifapentine and rifabutin against south Indian isolates of Mycobacterium tuberculosis. Indian J Tuberc 1993; 40(1): 17–20
13. 13. MD Yates CH Collins 1982 Comparison of the sensitivity of mycobacteria to the cyclopentyl rifamycin DL473 and rifampicin J Antimicrob Chemother 10 147 50 7118764 10.1093/jac/10.2.147 1:STN:280:DyaL3s%2Fgs12jsA%3D%3D Yates MD, Collins CH. Comparison of the sensitivity of mycobacteria to the cyclopentyl rifamycin DL473 and rifampicin. J Antimicrob Chemother 1982 Aug; 10: 147–50
14. 14. SL Moghazeh X Pan T Arain 1996 Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations Antimicrob Agents Chemother 40 2655 7 8913484 1:CAS:528:DyaK28Xms1Smt74%3D Moghazeh SL, Pan X, Arain T, et al. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 1996 Nov; 40: 2655–7
15. 15. Park YK, Cho SH, Shim MS, et al. Detection of rifampicin resistance in Mycobacterium tuberculosis by line probe assay [abstract no. U-16]. Abstr 97th Gen Meet Am Soc Microbiol, Miami Beach, Florida 1997 May 4–8: 546
16. 16. Williams DL, Spring L, Miller L, et al. Role of mutations in the rpoB of Mycobacterium tuberculosis and development of rifamycin cross-resistance [abstract no. U-8]. Abstr 97th Gen Meet Am Soc Microbiol, Miami Beach, Florida 1997 May 4–8: 545
17. 17. A Pascual D Tsukayama J Kovarik 1987 Uptake and activity of rifapentine in human peritoneal macrophages and polymorphonuclear leukocytes Eur J Clin Microbiol 6 152 7 2954817 10.1007/BF02018197 1:CAS:528:DyaL2sXlt1KmsL8%3D Pascual A, Tsukayama D, Kovarik J, et al. Uptake and activity of rifapentine in human peritoneal macrophages and polymorphonuclear leukocytes. Eur J Clin Microbiol 1987 Apr; 6: 152–7
18. 18. N Mor B Simon N Mezo 1995 Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages Antimicrob Agents Chemother 39 2073 7 8540718 10.1128/AAC.39.9.2073 1:CAS:528:DyaK2MXnvVygtrY%3D Mor N, Simon B, Mezo N. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob Agents Chemother 1995 Sep; 39: 2073–7
19. 19. CS Easmon JP Crane 1984 Comparative uptake of rifampicin and rifapentine (DL473) by human neutrophils J Antimicrob Chemother 13 585 91 6469880 10.1093/jac/13.6.585 1:CAS:528:DyaL2cXlt1Kltb4%3D Easmon CS, Crane JP. Comparative uptake of rifampicin and rifapentine (DL473) by human neutrophils. J Antimicrob Chemother 1984 Jun; 13: 585–91
20. 20. J Dhillon JM Dickinson JA Guy 1992 Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis Tuber Lung Dis 73 116 23 1643297 10.1016/0962-8479(92)90066-S 1:STN:280:DyaK38zltlChsQ%3D%3D Dhillon J, Dickinson JM, Guy JA, et al. Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tuber Lung Dis 1992 Apr; 73: 116–23
21. 21. C Truffot-Pernot J Grosset R Bismuth 1983 Activity of intermittently administered rifampicin and cyclopentyl rifamycin (or DL473) on experimental tuberculosis in the mouse [in French] Rev Fr Mal Respir 11 875 82 6669798 1:CAS:528:DyaL2cXhtFCls7Y%3D Truffot-Pernot C, Grosset J, Bismuth R, et al. Activity of intermittently administered rifampicin and cyclopentyl rifamycin (or DL473) on experimental tuberculosis in the mouse [in French]. Rev Fr Mal Respir 1983; 11: 875–82
22. 22. J Grosset N Lounis C Truffot-Pernot 1998 Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice Am J Respir Crit Care Med 157 5 1436 40 9603120 1:STN:280:DyaK1c3msVamuw%3D%3D Grosset J, Lounis N, Truffot-Pernot C, et al. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am J Respir Crit Care Med 1998 May; 157(5): 1436–40
23. 23. B Ji C Truffot-Pernot C Lacroix 1993 Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice Am Rev Respir Dis 148 1541 6 8256897 10.1164/ajrccm/148.6_Pt_1.1541 1:STN:280:DyaK2c%2FnvFSqsA%3D%3D Ji B, Truffot-Pernot C, Lacroix C, et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993 Dec; 148 (Pt 1): 1541–6
24. 24. L Chapuis B Ji C Truffot-Pernot 1994 Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice Am J Respir Crit Care Med 150 1355 62 7952564 1:STN:280:DyaK2M%2FktVaqtQ%3D%3D Chapuis L, Ji B, Truffot-Pernot C, et al. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med 1994 Nov; 150 (Pt 1): 1355–62
25. 25. BP Kelly SK Furney MT Jessen 1996 Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother 40 2809 12 9124846 1:CAS:528:DyaK28Xnt1Gnu7g%3D Kelly BP, Furney SK, Jessen MT, et al. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996 Dec; 40: 2809–12
26. 26. ACF Keung MG Eller S Gardner 1996 Pharmacokinetics of rifapentine in young women and elderly men [abstract] 36th Interscience Conference on Antimicrobial Agents and Chemotherapy 15 18 Keung ACF, Eller MG, Gardner S, et al. Pharmacokinetics of rifapentine in young women and elderly men [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy 1996 Sep 15: 18
27. 27. ACF Keung MG Eller SJ Weir 1998 Single-dose pharmacokinetics of rifapentine in elderly men Pharm Res 15 8 1286 91 9706063 10.1023/A:1011960428896 1:CAS:528:DyaK1cXltFynt74%3D Keung ACF, Eller MG, Weir SJ. Single-dose pharmacokinetics of rifapentine in elderly men. Pharm Res 1998; 15(8): 1286–91
28. 28. AC-F Keung TD Miller VI Green 1995 Bioavailability and food effect study of rifapentine in healthy adults [abstract] Pharm Res 12 S 419 Keung AC-F, Miller TD, Green VI, et al. Bioavailability and food effect study of rifapentine in healthy adults [abstract]. Pharm Res 1995 Sep; 12 Suppl.: S–419
29. 29. Data on file. Hoechst Marion Roussel, Inc. Kansas City (MO), USA
30. 30. SL Chan WW Yew JHD Porter 1994 Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals Int J Antimicrob Agents 3 267 74 18611569 10.1016/0924-8579(94)90054-X 1:CAS:528:DyaK2cXisFeitLY%3D Chan SL, Yew WW, Porter JHD, et al. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int J Antimicrob Agents 1994 Jan; 3: 267–74
31. 31. Taglietti M, Frigo GM, Cavenaghi L, et al. Pharmacokinetics of rifapentine in healthy volunteers [abstract no. 1015]. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy 1988 October: 290
32. 32. RCJ Owens A-F Keung S Gardner 1997 Pharmacokinetic and food effect evaluation of rifapentine in subjects seropositive for the human immunodeficiency virus [abstract no. A-2] Interscience Conference on Antimicrobial Agents and Chemotherapy 37 1 Owens RCJ, Keung AC-F, Gardner S, et al. Pharmacokinetic and food effect evaluation of rifapentine in subjects seropositive for the human immunodeficiency virus [abstract no. A-2]. Interscience Conference on Antimicrobial Agents and Chemotherapy 1997 37: 1
33. 33. CM Tam SL Chan CW Lam 1997 Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong Int J Tuberc Lung Dis 1 5 411 6 9441094 1:STN:280:DyaK1c%2FlvFGhsA%3D%3D Tam CM, Chan SL, Lam CW, et al. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int J Tuberc Lung Dis 1997 Oct; 1(5): 411–6
34. 34. CM Tam SL Chan CW Lam 1998 Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis initial report Am J Respir Crit Care Med 157 1726 33 9620898 1:STN:280:DyaK1c3osFyjtA%3D%3D Tam CM, Chan SL, Lam CW, et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis initial report. Am J Respir Crit Care Med 1998; 157: 1726–33
35. 35. RJ O’Brien AA Vernon 1998 New tuberculosis drug development. How can we do better? Am JRespir Crit Care Med 157 1705 7 O’Brien RJ, Vernon AA. New tuberculosis drug development. How can we do better? Am JRespir Crit Care Med 1998; 157: 1705–7
36. 36. K Reith A Keung PC Toren 1998 Disposition and metabolism of 14C-rifapentine in healthy volunteers Drug Metab Dispos 26 8 732 8 9698286 1:CAS:528:DyaK1cXlsVSru7Y%3D Reith K, Keung A, Toren PC, et al. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab Dispos 1998; 26(8): 732–8
37. 37. A Assandri B Ratti T Cristina 1984 Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit J Antibiot Tokyo 37 1066 75 6501103 10.7164/antibiotics.37.1066 1:CAS:528:DyaL2cXmtVertr8%3D Assandri A, Ratti B, Cristina T. Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. J Antibiot Tokyo 1984 Sep; 37: 1066–75
38. 38. QP Zhen P Chen JL Fen 1997 High performance liquid Chromatographic determination of anti-tuberculosis drugs in human body fluids J Liq Chromatogr Relat Techno 20 3 459 69 10.1080/10826079708010663 1:CAS:528:DyaK2sXhsFehtr0%3D Zhen QP, Chen P, Fen JL, et al. High performance liquid Chromatographic determination of anti-tuberculosis drugs in human body fluids. J Liq Chromatogr Relat Techno 1997; 20(3): 459–69
39. 39. Q Zhang Y Cao Y Zhang 1994 Clinical pharmacokinetic study on rifapentine [in Chinese] Chin J Antibiotics 19 6 456 8 1:CAS:528:DyaK2MXlsVKgtL4%3D Zhang Q, Cao Y, Zhang Y. Clinical pharmacokinetic study on rifapentine [in Chinese]. Chin J Antibiotics 1994; 19(6): 456–8
40. 40. ACF Keung MG Eller SJ Weir 1998 Phannacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction J Clin Pharmacol 38 517 24 9650541 1:CAS:528:DyaK1cXktleisr4%3D Keung ACF, Eller MG, Weir SJ. Phannacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction. J Clin Pharmacol 1998; 38: 517–24
41. 41. D Vital-Durand C Hampden AR Boobis 1986 Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative Br J Clin Pharmacol 21 1 7 3947503 10.1111/j.1365-2125.1986.tb02816.x 1:STN:280:DyaL287jtFehsQ%3D%3D Vital-Durand D, Hampden C, Boobis AR, et al. Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. Br J Clin Pharmacol 1986 Jan; 21: 1–7
42. 42. AP Li MK Reith A Rasmussen 1997 Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin Chemico-Biological Interactions 107 17 30 9402947 10.1016/S0009-2797(97)00071-9 1:CAS:528:DyaK2sXnt1eksLc%3D Li AP, Reith MK, Rasmussen A, et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chemico-Biological Interactions 1997; 107: 17–30
43. 43. A Vernon E Villarino R O’Brien 1997 Relapse with rifampin mono-resistant TB (RMR-TB) in HIV-positive TB patients treated with a once weekly rifapentine-containing regimen [abstract no. 357-PA02] Int J Tuberc Lung Dis 1 5 S51 2 Vernon A, Villarino E, O’Brien R, et al. Relapse with rifampin mono-resistant TB (RMR-TB) in HIV-positive TB patients treated with a once weekly rifapentine-containing regimen [abstract no. 357-PA02]. Int J Tuberc Lung Dis 1997; 1(5) Suppl. A: S51–2
44. 44. A Vernon A Khan L Bozeman 1998 Update on US public health service (USPHS) study 22: a trial of once weekly isoniazid (INH) & rifapentine (RPT) in the continuation phase of TB treatment [abstract] Am J Respir Crit Care Med 157 A467 Vernon A, Khan A, Bozeman L, et al. Update on US public health service (USPHS) study 22: a trial of once weekly isoniazid (INH) & rifapentine (RPT) in the continuation phase of TB treatment [abstract]. Am J Respir Crit Care Med 1998 Mar; 157 (3 Pt 2): A467
45. 45. BY Yan 1992 A controlled clinical trial of rifapentine containing chemotherapy regimens for bacillary tuberculosis: results at three years [in Chinese] Chin J Antibiotics 17 5 313 22 Yan BY et al. A controlled clinical trial of rifapentine containing chemotherapy regimens for bacillary tuberculosis: results at three years [in Chinese]. Chin J Antibiotics 1992; 17(5): 313–22
46. 46. GJ He 1993 A comparative study of rifapentine treatment and three years follow-up on initial pulmonary tuberculous [in Chinese] Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih 16 73 6 8251027 1:STN:280:DyaK2c%2FjslWrsw%3D%3D He GJ et al. A comparative study of rifapentine treatment and three years follow-up on initial pulmonary tuberculous [in Chinese]. Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih 1993 Feb; 16: 73–6, 122